224 results about "A baumannii" patented technology

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP1111NC, and is obtained by performing N-terminal acetyl end capping and C-terminal amino end capping on polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1, the number of amino acids is small, the synthesis cost is low, the antibacterial peptide has high antibacterial activity on gram-negative bacteria and gram-positive bacteria, the minimum inhibitory concentration of the antibacterial peptide on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is 4.68-37.5 mu g / mL, and the antibacterial peptide has the advantages of broad-spectrum antibacterial property, good stability and good application prospect. No obvious cytotoxicity and hemolysis effect exist; moreover, end-to-end amido bond cyclization is carried out, so that the antibacterial activity is further enhanced, the antibacterial effect on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is enhanced by 2-4 times, and the minimum inhibitory concentration is reduced to 2.34-9.38 mu g / mL; after the end-to-end amido bonds are cyclized, the plasma stability and safety of the antibacterial peptide are further improved, and the cytotoxicity and hemolysis are reduced.

The invention relates to the technical field of high-throughput targeted sequencing, in particular to a primer group for detecting important drug-resistant genes and virulence genes of multi-drug-resistant pathogenic bacteria and application of the primer group. Specifically, the kit comprises detection primers for multiple drug-resistant bacteria such as third-generation cephalosporin drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant enterobacteriaceae bacteria, carbapenem drug-resistant acinetobacter baumannii, rifampicin drug-resistant mycobacterium tuberculosis and the like. The method has the technical advantages of rapidness, high efficiency, strong targeting property, strong specificity and the like, is suitable for epidemic and difference analysis of various important drug-resistant genes and virulence genes carried by metagenome samples of various environments or disease materials and the like, evaluates the risk of related environments on the basis, and can further guide prevention and clinical treatment medication.

The present invention provides an ATP phosphoribosyltransferase mutant and its application in histidine production. The mutant is obtained by performing point mutations at positions 84 and / or 205 on the amino acid sequence of the wild-type ATP phosphoribosyltransferase derived from Acinetobacter baumannii. The mutant, the nucleic acid molecule encoding the mutant, the expression cassette containing the nucleic acid molecule, the recombinant vector or the recombinant microorganism are used for the production of L-histidine, and the yield of L-histidine is significantly increased, laying a good foundation for the large-scale industrial production of L-histidine.

The invention belongs to the technical field of medicines, and discloses a near-infrared cyanine probe for detecting penicillin G acylase as well as a preparation method and application of the near-infrared cyanine probe. According to the research, a near-infrared fluorescent probe Cy-NEO-PA responding to penicillin G acylase (PGA) is developed, so that the influence of environmental factors on the formation of an acinetobacter baumannii biological membrane is observed. Research results show that glucose inhibits the generation of PGA to enhance the formation of a biological membrane, while phenylacetic acid (PAA) stimulates the generation of PGA and inhibits the formation of the biological membrane. The observation results highlight the excellent capability of Cy-NEO-PA in accurately measuring PGA kinetics, and reveal the key effect of PGA in biological membrane development. In addition, the Cy-NEO-PA has good biocompatibility, strong active oxygen generation, efficient photo-thermal conversion and bacterial targeting ability, so that the Cy-NEO-PA becomes a promising drug for resisting bacterial infection and promoting wound healing through photo-thermal / photodynamic therapy.

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention discloses application of acinetobacter baumannii bacteriophage depolymerases in preparation of bacteriostatic agents, and relates to the technical field of biology. The depolymerases disclosed by the invention can inhibit the growth of a plurality of acinetobacter baumannii, have a bacteriostatic effect on the acinetobacter baumannii, and lay a foundation for developing effective infection control strategies and treatment methods to resist infection of the multi-drug-resistant acinetobacter baumannii.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention discloses acinetobacter baumannii and application of the acinetobacter baumannii in construction of a mastitis animal model. The acinetobacter baumannii strain is acinetobacter baumannii AbST3475NMG202308, and the preservation number of the acinetobacter baumannii strain is CGMCC (China General Microbiological Culture Collection Center) No.34450 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms). Experiments prove that the acinetobacter baumannii has high pathogenicity and can be used for establishing a typical animal model caused by acinetobacter baumannii infection, the animal model can be specifically a mastitis animal model, and a certain technical support is provided for subsequent research and development of drugs or vaccines; the acinetobacter baumannii can also be used for screening antibacterial drugs and developing diagnostic reagents and vaccines. The method has an important application value.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention provides a fluorenyl alcohol derivative which can be used as an antibiotic adjuvant with a broad-spectrum synergistic effect. According to the compound, bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are taken as targets, and a series of fluorenyl alcohol derivatives targeting the bacteria outer membrane asymmetric protein MlaC and phospholipase A1 PldA are obtained through screening. The preferable compound WTU-15 can improve the antibacterial activity of antibiotics such as polymyxin, cefepime, tetracycline and the like on negative bacteria such as sensitive and drug-resistant escherichia coli, salmonella, klebsiella pneumoniae, acinetobacter baumannii and the like, and can also improve the in-vivo treatment effect of cefepime on mice infected by the drug-resistant acinetobacter baumannii. And the visceral organs of the mice survived after administration have fewer bacteria, and the mice are better after being healed. Normal physiological and visceral organ functions of the mouse are not affected by single and continuous administration of the WTU-15.

The present invention relates to the technical field of phages. Provided are a KL2-type Acinetobacter baumannii phage and a screening method therefor, a phage composition and the use, and a drug. The KL2-type Acinetobacter baumannii phage is named AB_SZL2, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241522; or the KL2-type Acinetobacter baumannii phage is named AB_SZL3, and is deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M20241523. The KL2-type Acinetobacter baumannii phage can accurately target KL2-type Acinetobacter baumannii, and has an efficient bactericidal effect, thereby reducing the harm of KL2-type Acinetobacter baumannii and effectively addressing the problem of the antibiotic resistance of KL2-type Acinetobacter baumannii.

The invention belongs to the field of antibacterial peptides, and particularly relates to an antibacterial peptide with a broad-spectrum antibacterial effect, an antibacterial product and application. The antibacterial peptide is named as CAMP502NC, and is obtained through N-terminal acetyl end capping and C-terminal amino end capping of polypeptide shown in SEQ ID NO: 1. The antibacterial peptide has remarkable antibacterial activity on a staphylococcus aureus standard strain ATCC12600, pseudomonas aeruginosa PAO1, klebsiella pneumoniae, an acinetobacter baumannii standard strain ATCC19606, methicillin-resistant staphylococcus aureus ATCC33591, methicillin-resistant and gentamicin-resistant staphylococcus aureus ATCC33592 and acinetobacter baumannii bio-53272 resistant to various antibiotics, and the antibacterial peptide can be used for preparing the antibacterial peptide. The limitation of the traditional antibacterial peptide is effectively overcome.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The invention belongs to the technical field of bacterium detection, and discloses a multiple PCR primer for simultaneously detecting eight respiratory tract pathogenic bacteria and application thereof. On the basis of a Luminex liquid phase chip technology, specific primers are designed aiming at eight common respiratory tract infection pathogenic bacteria including pseudomonas aeruginosa, staphylococcus aureus, streptococcus pneumoniae, klebsiella pneumoniae, acinetobacter baumannii, stenotrophomonas maltophilia, haemophilus influenzae and escherichia coli; the multiple PCR primers which are high in amplification efficiency, good in specificity and suitable for simultaneously detecting the eight respiratory tract pathogenic bacteria are screened out, the multiple PCR system and microsphere hybridization conditions are continuously optimized, the multiple PCR method for the eight respiratory tract pathogenic bacteria is successfully constructed by applying the Luminex xTAG technology, and the multiple PCR method can be applied to rapid detection of multiple pathogenic microorganisms.

The invention discloses application of a cyclic peptide compound BIM 23042 or a preparation thereof in preparation of medicines for treating bacterial infectious diseases, and belongs to the technical field of medicines. The invention discloses a cyclic peptide compound BIM 23042 as an antibiotic synergist for the first time, and the cyclic peptide compound BIM 23042 is used for treating bacterial infectious diseases. According to the application disclosed by the invention, the cyclopeptide compound BIM 23042 and polymyxin are combined for use, so that the growth of gram-negative bacteria can be effectively and synergistically inhibited. The combined medication scheme shows a remarkable advantage in coping with acinetobacter baumannii. The cyclic peptide compound BIM 23042 disclosed by the invention has an anti-infection capability, and the anti-infection capability is specifically shown as reducing the inflammatory response of macrophage RAW 264.7 induced by LPS (Lipopolysaccharide) and also reducing the apoptosis of the macrophage RAW 264.7 caused by the LPS. The invention provides a new perspective for developing a novel drug-resistant gram-negative bacterium prevention and control strategy, and also provides a new treatment scheme for coping with bacterial infection.

The invention belongs to the technical field of strain identification and drug sensitivity detection, and discloses a strain identification and drug sensitivity detection kit and a preparation method and application thereof, the kit comprises a drug sensitivity disc, a pre-enrichment chromogenic culture medium, a chromogenic culture medium, sterile water and a diluent; the drug sensitive disc body comprises an enterobacteriaceae area, an enterococcus area, a staphylococcus area, a pseudomonas aeruginosa area and an acinetobacter baumannii area; the enterobacteriaceae area is provided with enterobacteriaceae identification culture medium micropores and drug micropores, the enterococcus area is provided with enterococcus identification culture medium micropores and drug micropores, the staphylococcus area is provided with staphylococcus identification culture medium micropores and drug micropores, and the pseudomonas aeruginosa area is provided with pseudomonas aeruginosa identification culture medium micropores and drug micropores. An acinetobacter baumannii identification culture medium micropore and a medicine micropore are matched in the acinetobacter baumannii area; the problems that an existing drug sensitivity test mode is complex in operation, high in cost and low in accuracy of identification and detection results are solved.

The invention discloses a novel acinetobacter baumannii phage vBAbaMpha0264 and application thereof, and belongs to the technical field of microorganisms. The acinetobacter baumannii phage vBAbaMpha0264 is preserved in the Guangdong Microbiological Culture Collection Center on August 28, 2025, the preservation number of the acinetobacter baumannii phage vBAbaMpha0264 is GDMCC (China General Microbiological Culture Collection Center) NO: 66893-B1, and the preservation address of the acinetobacter baumannii phage vBAbaMpha0264 is Institute of Microbiology, Academy of Sciences, Guangdong. The bacteriophage vBAbaMpha0264 has high cracking activity, environmental stability and safety, shows a breakthrough host range, and can be used for effectively cracking a plurality of acinetobacter bacteria including hospital acinetobacter and acinetobacter sysei. Meanwhile, the bacteriophage has excellent chloroform tolerance, and the stability of the bacteriophage is obviously superior to that of the existing bacteriophage. Due to the characteristics, the phage vBAbaMpha0264 overcomes the technical prejudice of'narrow spectrum and instability 'of the traditional phage, and a brand new technical scheme is provided for developing a universal antibacterial preparation covering more pathogenic bacteria.

The invention belongs to the technical field of medicines, and particularly relates to an aryl dicarboxylic acid compound, a preparation method and application of the aryl dicarboxylic acid compound as an antibacterial agent. The compound is shown as a formula (1), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are independently selected from hydrogen and halogen. Two ends of the molecule are connected through an N-phenylpropanamide connecting arm, the molecule is a compound with a novel structure, and the series of compounds have a relatively strong inhibition effect on acinetobacter baumannii and are worthy of further research and development.

The application belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mp-GC21, a precursor thereof and application. The amino acid sequence of the antibacterial peptide Mp-GC21 is shown as SEQ ID NO:1, wherein the C terminal is subjected to amidation modification, and two cysteines are connected through a disulfide bond; and the amino acid sequence of the precursor is shown as SEQ ID NO:3. The antibacterial peptide Mp-GC21 is separated from the flower frog, has broad-spectrum antibacterial activity, and has good bacteriostatic and bactericidal effects on standard strains and clinically derived drug-resistant strains of Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and can target to destroy the cell membrane of bacteria, remove the biofilm and inhibit the formation of the biofilm. Moreover, the antibacterial peptide Mp-GC21 has good stability, does not have hemolytic activity, cytotoxicity and in-vivo toxicity, and is not easy to induce drug resistance of strains.

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The invention relates to the technical field of bacteriophages, and particularly discloses an acinetobacter baumannii bacteriophage, depolymerases and a preparation method and application of the acinetobacter baumannii bacteriophage. The acinetobacter baumannii bacteriophage P919 provided by the invention has very strong specific lysis capability on KL3 type acinetobacter baumannii, and the coded depolymerases of the acinetobacter baumannii bacteriophage P919 have excellent temperature stability at 70 DEG C or below, and can effectively degrade capsular polysaccharide of the KL3 type acinetobacter baumannii.

The invention discloses an antibody as well as a preparation method and application thereof. The antibody has good binding activity with OXA-23 type carbapenem enzyme, and can reduce the carbapenem drug resistance level of the acinetobacter baumannii, so that the clinical use concentration of meropenem is reduced, and the treatment effect of meropenem on the acinetobacter baumannii is improved. In addition, the antibody disclosed by the invention can also inhibit OXA-23 protein secreted by bacteria, prevent the bacteria from hydrolyzing carbapenem antibiotics, increase the concentration of antibiotics in a medication part, and facilitate the removal of mixed infection with acinetobacter baumannii. The invention provides a new strategy for treating acinetobacter baumannii infection, and the application prospect is wide.

The present invention relates to the technical field of antimicrobial peptides, and discloses a Doudnabacteria antimicrobial peptide and its application. The amino acid sequence of the antimicrobial peptide is shown in SEQ ID NO: 1. The antimicrobial peptide obtained by the present invention has a good antibacterial effect on Staphylococcus aureus, Klebsiella pneumoniae, Listeria monocytogenes, and Acinetobacter baumannii.

The invention discloses a strain of lactobacillus muricatum and application thereof.The lactobacillus muricatum SZH025 obtained through the method has an obvious inhibiting effect on acinetobacter baumannii, klebsiella pneumoniae and escherichia coli under the in-vitro condition and is suitable for preventing and treating intestinal infectious diseases or adjusting intestinal flora; the cholate hydrolase (BSH) activity is remarkable, bile acid metabolism is facilitated, cholesterol excretion is promoted, and the blood fat reducing and regulating effects are achieved. In addition, the strain shows good safety characteristics, has relatively strong gastrointestinal tract environmental adaptability, has certain antioxidant function and ethanol decomposition capacity, is beneficial to alcohol metabolism, can produce oleic acid, and has potential probiotic effects of regulating lipid, resisting inflammation and improving the metabolic state of a host.

The invention discloses a kit and a device for detecting acinetobacter baumannii. The kit comprises a first primer, a second primer, recombinase polymerase, Cas12a protein, crRNA and ssDNA, wherein the sequence of the first primer is as shown in SEQ ID NO.1; the sequence of the second primer is as shown in SEQ ID NO. 2; the sequence of the crRNA is as shown in SEQ ID NO.3, the crRNA is modified with a light-sensitive chemical group for preventing the combination of the crRNA and target nucleic acid, and the light-sensitive chemical group falls off from the crRNA when irradiated by light with a predetermined wavelength; the sequence of the ssDNA is as shown in SEQ ID NO.4, one end of the ssDNA is modified with a fluorophore, and the other end of the ssDNA is modified with a quenching group. By adopting the kit or the device provided by the invention, the acinetobacter baumannii can be accurately detected, the working efficiency can be improved, and the risk of cross contamination can be reduced.

The application belongs to the technical field of medicine, and particularly relates to a cyclic peptide compound and application thereof in the field of antibiosis. The application discloses a cyclic peptide compound, the structure of which is shown as formula I. The preliminary experiment verifies that the compound has good effects of resisting Acinetobacter baumannii, and has wide application prospects.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Z34B3 and application thereof. The amino acid sequence of the antibacterial peptide Z34B3 provided by the invention is shown as SEQ ID NO: 1, the secondary structure is an alpha helix, the molecular weight is small, and the antibacterial peptide Z34B3 can change the cell membrane permeability of various gram-negative bacteria including pasteurella multocida, escherichia coli and acinetobacter baumannii, inhibit the generation of cell membranes and play antibacterial and bactericidal roles. Moreover, the antibacterial peptide Z34B3 provided by the invention has low hemolytic activity and no cytotoxicity, and can be applied to preparation of products with bacteriostatic and bactericidal effects and preparation of drugs for preventing and / or treating bacterial infectious diseases. Furthermore, the C tail end of the antibacterial peptide Z34B3 is subjected to amidation modification, and compared with non-modification treatment, the stability can be improved.

The invention discloses a preparation method and application of a broad-spectrum bactericidal boron carbide material based on a biomass carbon source. Biomass wastes such as cotton and corn stigma are used as carbon sources, and the high-hardness B4C nanowire is synthesized through a gas-liquid-solid catalytic growth process. The nanowire material realizes 100% inactivation on gram positive / negative bacteria such as staphylococcus aureus, escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii under the ultralow concentration of 10 mu g / mL through the mechanical piercing effect of nanowires, no chemical agent is needed in the whole process, and the risk of drug resistance is thoroughly avoided. Meanwhile, biomass waste is used for replacing a traditional high-purity carbon source, the raw material cost is greatly reduced, and the preparation method is simple and suitable for industrial large-scale production and application.